- Adults (18-64 years)
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Telemedicine
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Psychotherapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Digital health
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Psychotherapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Antivirals
- Tecovirimat
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- Elderly (≥65 years)
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Lifestyle intervention
- Education
- Therapeutic Exercise
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Anti-depressant
- Tianeptine
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- Telemedicine
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Breathing therapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Hyperbaric
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Dietary
- Psychotherapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation